Verastem, Inc. (VSTM)
8.20
+0.22
(+2.76%)
USD |
NASDAQ |
Sep 04, 16:00
8.10
-0.10
(-1.22%)
After-Hours: 20:00
Verastem Research and Development Expense (Quarterly) : 41.34M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 41.34M |
| March 31, 2026 | 38.22M |
| December 31, 2025 | 31.68M |
| September 30, 2025 | 28.99M |
| June 30, 2025 | 24.79M |
| March 31, 2025 | 29.15M |
| December 31, 2024 | 20.81M |
| September 30, 2024 | 24.75M |
| June 30, 2024 | 18.06M |
| March 31, 2024 | 17.71M |
| December 31, 2023 | 22.50M |
| September 30, 2023 | 13.95M |
| June 30, 2023 | 12.89M |
| March 31, 2023 | 12.02M |
| December 31, 2022 | 10.74M |
| September 30, 2022 | 11.29M |
| June 30, 2022 | 14.89M |
| March 31, 2022 | 13.64M |
| December 31, 2021 | 11.40M |
| September 30, 2021 | 9.325M |
| June 30, 2021 | 9.73M |
| March 31, 2021 | 8.896M |
| December 31, 2020 | 10.15M |
| September 30, 2020 | 10.59M |
| June 30, 2020 | 9.344M |
| Date | Value |
|---|---|
| March 31, 2020 | 10.92M |
| December 31, 2019 | 12.46M |
| September 30, 2019 | 12.22M |
| June 30, 2019 | 11.35M |
| March 31, 2019 | 9.758M |
| December 31, 2018 | 8.762M |
| September 30, 2018 | 11.57M |
| June 30, 2018 | 12.38M |
| March 31, 2018 | 10.93M |
| December 31, 2017 | 11.25M |
| September 30, 2017 | 17.74M |
| June 30, 2017 | 9.042M |
| March 31, 2017 | 8.385M |
| December 31, 2016 | 6.892M |
| September 30, 2016 | 4.216M |
| June 30, 2016 | 4.492M |
| March 31, 2016 | 4.179M |
| December 31, 2015 | 7.688M |
| September 30, 2015 | 11.30M |
| June 30, 2015 | 11.04M |
| March 31, 2015 | 10.53M |
| December 31, 2014 | 9.685M |
| September 30, 2014 | 9.047M |
| June 30, 2014 | 8.305M |
| March 31, 2014 | 8.411M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Dianthus Therapeutics, Inc. | 48.69M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| Anika Therapeutics, Inc. | 7.341M |
| Savara, Inc. | 21.95M |